Furthermore, the inhibition of angiogenesis in HCC was investigated with the anti-VEGF receptor 2 (VEGFR2) monoclonal antibody ramucirumab in the REACH trial (NCT01140347) and in the REACH-2 trial (NCT02435433). This evidence concerns the gene KDR and hepatocellular carcinoma.